ESMO 2022 | Personalized medicine in early-stage TNBC

Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, discusses the implementation of personalized medicine in early breast cancer. Dr Gluz touches on the role of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) as a prognostic marker for treatment escalation/de-escalation. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.